
- /
- Supported exchanges
- / US
- / MKKGY.PINK
Merck KGaA ADR (MKKGY PINK) stock market data APIs
Merck KGaA ADR Financial Data Overview
Merck KGaA operates as a science and technology company in Germany and internationally. It operates through Life Science, Healthcare, and Electronics segments. The Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as the industrial sector. This segment offers science and lab solutions comprising reagents, consumables, devices, instruments, software, and services for research, production, and testing; process solutions consisting of filtration devices, chromatography resins, single-use systems, process chemicals, and excipients; and life science services, such as monoclonal antibodies, high-potency active pharmaceutical ingredients, antibody-drug conjugates, and viral and gene therapy products, as well as contract development, manufacturing, and testing services. Its Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, cardiovascular, metabolism, and endocrinology disorders; and provides general medicines, injection devices, and disease monitoring software. The Electronics segment supplies materials comprising thin films, patterning and planarization formulations, specialty gases, optronics, and optical metrology equipment for the semiconductor and display industries, as well as provides delivery systems and services. It has in-licensing agreements with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Merck KGaA ADR data using free add-ons & libraries
Get Merck KGaA ADR Fundamental Data
Merck KGaA ADR Fundamental data includes:
- Net Revenue: 21 219 M
- EBITDA: 5 953 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: 0.4874
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Merck KGaA ADR News

Global Biopreservation Market Set to Surpass USD 7.1 Billion by 2029 | MarketsandMarkets™
MarketsandMarkets Research Pvt. Ltd. Advancements in healthcare expenditure, research investment, and regenerative medicine are fueling growth while storage logistics remain a critical challenge Del...


Multi-Plex Immunoassays Market to Reach US$ 6.90 Billion by 2033 as Precision Medicine and Biomarker Discovery Fuel Global Adoption | DataM Intelligence
AUSTIN, Texas and TOKYO, Oct. 7, 2025 /PRNewswire/ -- The Multi-Plex Immunoassays Market is entering a new era of growth as clinical diagnostics, drug discovery, and personalized medicine increasingl...

How Does Merck KGaA's (XTRA:MRK) Genome Editing Push Reshape Its Innovative Edge?
Merck KGaA participated in the Drug Discovery Innovation Programme 2025 in Barcelona from September 25-26, 2025, with presentations by Angelo Lanzilotto and Thomas Fuchss focusing on digital and medic...

Genome Editing Market Report 2025: CRISPR and Beyond - Emerging Technologies Reshape Biopharmaceutical Landscape
Company Logo The report provides a comprehensive analysis of the genome editing market, focusing on technologies like CRISPR-Cas, TALEN, and ZFN. It assesses applications across biopharma, ag biotech...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.